Tag:
Stryker
Latest Headlines
Latest Headlines
Purdue U., U.S. Army explore nanotech-coated stent to combat brain aneurysms
Purdue University scientists are studying whether stents coated with a nanotechnology-enhanced drug could serve as potent treatment for aneurisms. And a lead researchert involved in the effort will speak before Congress on May 24 to talk about how nanotechnology could help treat brain injury and disease.
NeuroLogica, Stryker enter BodyTom pact
Boston-area NeuroLogica is teaming up with Stryker's navigation unit as the two work to offer surgeons better orientation in the OR.
Study: Metal hips don't heighten cancer risks
For all the bad press metal-on-metal hips generate these days over potential malfunctioning and other safety concerns, a new study offers a small piece of good news: The implants don't appear to boost cancer risks after their first 7 years of use.
MHRA urges docs to avoid some metal hips
The bad news just keeps on coming in for manufactures of metal-on-metal hips. This morning, Johnson & Johnson ( $JNJ ) and Stryker ( $SYK ) are feeling the heat from the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA).
FDA could revoke Stryker Wingspan brain stent approval
Stryker's Wingspan intracranial stent faces an uncertain future in the U.S. market.
FDA knocks Stryker's Wingspan stent
Stryker is facing a sobering FDA report that points to the company's Wingspan stent as being more damaging than helpful in some cases and of neutral benefit in others, according to a Bloomberg story.
Was Stryker's MacMillan ousted?
The recent announcement that Stephen MacMillan was leaving Stryker ( $SYK ) sent shockwaves through the device community. But the story has taken quite a strange turn, as it has been revealed that he...
Stryker's Hartman sees salary boosted to $750K, MacMillan negotiates separation agreement
In the wake of his abrupt resignation, CEO Stephen MacMillan is still working out the specific details of his separation agreement with Stryker ( $SYK ). Meanwhile, interim CEO Curt Hartman, who also
What's next for Stryker after MacMillan's exit?
With the sudden departure of Stryker ( $SYK ) CEO Stephen MacMillan (pictured), analysts are wondering whether his successor will continue his growth strategy. And some are even asking if his departure
J&J, Stryker execs predict elective surgeries to rebound
Johnson & Johnson ( $JNJ ) and Stryker ( $SYK ) executives are predicting a rebound in elective surgeries as patients decide to undergo procedures they've been putting off due to the economy.
